Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series

BACKGROUND: In March, 2007, a black box warning was issued by the Food and Drug Administration (FDA) to use the lowest possible erythropoiesis-stimulating agents (ESA) doses for treatment of anemia associated with renal disease. The goal is to determine if a change in ESA use was observed following...

Descripción completa

Detalles Bibliográficos
Autores principales: Thamer, Mae, Zhang, Yi, Lai, Dejian, Kshirsagar, Onkar, Cotter, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751481/
https://www.ncbi.nlm.nih.gov/pubmed/23927675
http://dx.doi.org/10.1186/1471-2369-14-172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751481/
https://www.ncbi.nlm.nih.gov/pubmed/23927675
http://dx.doi.org/10.1186/1471-2369-14-172

Ejemplares similares